CD40LG and malaria: Thus, the kinetic properties of mAbs D2 and F9 make them potential candidates for malaria RDTs, and are at least comparable to the commercially available mAb C1-13, which has been shown to be superior to PfHRP2-specific IgM isotype antibodies [23].